Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from MarketBeat

Synopsys Stock Falls on China Ban, But Long-Term Outlook Holds

Synopsys is caught up in the U.S.-China trade war. Is this a reason to run, or is the long-term upside still in play for this essential chip-design enabler?

MarketBeat

Alphabet Enters a Bull Market: Is It Time to Buy?

Shares of Alphabet (GOOGL) have re-entered a bull market, climbing over 25% from its 52-week low and reclaiming the 200-day SMA.

MarketBeat

Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones

Ouster's Department of Defense win just sent shares skyrocketing. Its OS1 sensor now has Blue UAS approval, allowing a streamlined path for use in DoD drones.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

MarketBeat Week in Review – 06/09 - 06/13

Stocks swung between gains and losses as volatility continues to drive the market; next week the Federal Reserve is expected to leave rates unchanged

MarketBeat

IBM Up 10 Days in a Row: What’s Driving the Winning Streak?

IBM reached new all-time highs following a 10-day winning streak, but how long will the rally go? Read on to learn why IBM's strength will continue in 2025.

MarketBeat

Upstart Stock’s Bull Case Just Got a Lot Stronger

Today's economy is set up to benefit a stock like Upstart, giving its business model all the right reasons to bring the stock higher in price.

MarketBeat

Higher Gulf Oil Output Puts These Energy Names in Play

Today's economic cycle places a lot of high upside potential in the energy sector, sending waves of bullishness in these 3 names.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

UnitedHealth Stock Dips: Is This a Value Buy Opportunity?

UnitedHealth Group's recent dividend boost and strategic divestiture efforts, combined with executive stock purchases, highlight its strong investment appeal.

MarketBeat

Analysts Love Lovesac, But Investors Should Be Cautious

The Lovesac Company is on track to stage a significant stock price rebound, despite the risks remaining. A threat of dilution and high short interest cap gains.

MarketBeat

Intel's Price Spikes: Noise, or the First Notes of a Turnaround?

Intel's recent stock volatility is fueled by foundry commitments and a renewed internal focus on profitability, suggesting a strengthening recovery.

MarketBeat

SoFi Stock’s Next Test: Can It Justify Its Premium Valuation?

SOFI stock is up more than 25% in the last three months, but despite the company overcoming numerous obstacles, a P/E ratio of 40x may cap further upside

MarketBeat

Super Micro Computer Stock: 2 Levels Smart Money Is Watching

Super Micro Computer's chart shows investors two key levels to watch out for when developing a potential buy thesis for the coming months.

MarketBeat

Fastenal Stock After Split: Poised for 5 More Years of Gains

Fastenal has nearly doubled investors’ money over the past five years, and its fundamental strength positions the company for continued growth and future gains.

MarketBeat

Gold and Commodities: Is the Bull Case Gaining Momentum?

Gold has soared to new highs in 2025, but what's driving the rally and how much upside is left? Read on to learn why the gold rush isn't fading any time soon.

MarketBeat

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

Ignore the Noise—Samsara Stock Is Still a Strong Buy

Shares of Samsara have dipped after last week's earnings. But the fundamentals are on fire and analysts see 35% upside - get excited.

MarketBeat

3 Stocks Set to Double—And There's Still Time to Buy

Momentum investing always carries risks, but these three stocks with the potential to more than double are worth a closer look.

MarketBeat

Analysts Can't Get Enough of These Little-Known Biopharma Stocks

Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development.

MarketBeat

IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA

IonQ just hit investors with two pieces of big news. One shows proof of the company's tech being useful near-term. The other looks to aid its long-term goals.

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

Betting on Disruption: Is Lemonade the Future of Insurance?

Lemonade's AI-driven model is fueling accelerating growth and forging a clear, data-driven path toward sustained profitability in the insurance industry.

MarketBeat

Oracle’s Cloud Boom Is Just Getting Started

Oracle's game-changing guidance shifted the market into high gear and now a significant upside is indicated, potentially adding 50% to the stock price this year

MarketBeat

Netflix Sets New Highs—Price Targets Keep Climbing

Shares of Netflix have been hitting fresh all time highs after bullish analyst updates. With more upside forecasted, the rally is far from over.

MarketBeat

Starbucks Stock: Culture Fix May Be Key to Long-Term Growth

SBUX stock may offer long-term value if the turnaround takes root,however financial and cultural headwinds may limit the stock gains in the short term

MarketBeat

Alibaba’s Dip Is a Gift—Here’s the Price That Matters

Alibaba's chart shows a clear footprint of institutional buying, and also an opportunity for investors to start buying up at these ranges.

MarketBeat

3 Summer Stocks With Insider Buying and Analyst Support

These three consumer discretionary stocks have shown strong recent insider buying along with bullish analyst sentiment that supports a potential swing trade

MarketBeat

Wall Street Sees More Upside for Dell and HPE

Dell and HPE got a slew of Wall Street upgrades after earnings. But, shares have barely budged since. Is there untapped opportunity in these AI server makers?

1 2 3 4 5

People

Gabriel OsorioMazilli

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.